Abstract
Stem cells have unique properties that make them an exceptional source for regenerative medicine. Various types of stem cells and their products are used for therapeutic purposes, and they differ in their morphology, molecular markers, and functional characteristics. Nevertheless, to comply with regulatory requirements, strict criteria must be fulfilled. Here, we provide a comprehensive overview of the characterization criteria for human mesenchymal stem cells (hMSCs), human neural stem cells (hNSCs), human pluripotent stem cells (hPSCs), and human hematopoietic stem cells (hHSCs) that constitute the starting material for cell therapy products.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amit M, Itskovitz-Eldor J (2012) Morphology of human embryonic and induced pluripotent stem cell colonies cultured with feeders. In: Amit M, Itskovitz-Eldor J (eds) Atlas of human pluripotent stem cells. Humana Press, Totowa, NJ, pp 15–39. https://doi.org/10.1007/978-1-61779-548-0_2
Andrews P, Baker D, Benvinisty N, Miranda B, Bruce K, Brüstle O, Choi M et al (2015) Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen Med 10(2s):1–44. https://doi.org/10.2217/rme.14.93
Baghbaderani BA, Tian X, Neo BH, Burkall A, Dimezzo T, Sierra G, Zeng X et al (2015) cGMP-manufactured human induced pluripotent stem cells are available for pre-clinical and clinical applications. Stem Cell Rep 5(4):647–659. https://doi.org/10.1016/j.stemcr.2015.08.015
Baker EW, Kinder HA, West FD (2019) Neural stem cell therapy for stroke: a multimechanistic approach to restoring neurological function. Brain Behav 9(3):e01214. https://doi.org/10.1002/brb3.1214
Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Büscher D et al (2013) Risk of tumorigenicity in mesenchymal stromal cell–based therapies—bridging scientific observations and regulatory viewpoints. Cytotherapy 15(7):753–759. https://doi.org/10.1016/j.jcyt.2013.03.005
Bieback K, Kuçi S, Schäfer R (2019) Production and quality testing of multipotent mesenchymal stromal cell therapeutics for clinical use. Transfusion 59(6):2164–2173. https://doi.org/10.1111/trf.15252
Boese AC, Le Q-SE, Pham D, Hamblin MH, Lee J-P (2018) Neural stem cell therapy for subacute and chronic ischemic stroke. Stem Cell Res Ther 9(1):154. https://doi.org/10.1186/s13287-018-0913-2
Carpenter MK (2017) Chapter 6—regulatory considerations for pluripotent stem cell therapies. In: Dunnett SB, Björklund A (eds) Progress in brain research. Functional neural transplantation IV, vol 230. Elsevier, pp 151–163. https://doi.org/10.1016/bs.pbr.2016.12.008
Castillo N, García-Cadenas I, Barba P, Martino R, Azqueta C, Ferrà C, Canals C, Sierra J, Valcárcel D, Querol S (2015) Post-thaw viable CD45+ cells and clonogenic efficiency are associated with better engraftment and outcomes after single cord blood transplantation in adult patients with malignant diseases. Biol Blood Marrow Transpl 21(12):2167–2172. https://doi.org/10.1016/j.bbmt.2015.08.016
Chen Y-M, Chen L-H, Li M-P, Li H-F, Akon H, Suresh Kumar S, Ling Q-D et al (2017) Xeno-free culture of human pluripotent stem cells on oligopeptide-grafted hydrogels with various molecular designs. Sci Rep 7(1). https://doi.org/10.1038/srep45146
Considerations for the design of early-phase clinical trials of cellular and gene therapy products; Guidance for Industry (2015) U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-early-phase-clinical-trials-cellular-and-gene-therapy-products
Conti L, Pollard SM, Gorba T, Reitano E, Toselli M, Biella G, Sun Y et al (2005) Niche-independent symmetrical self-renewal of a mammalian tissue stem cell. Editoval Robin Lovell-Badge. PLoS Biol 3(9):e283. https://doi.org/10.1371/journal.pbio.0030283
Daughtry B, Mitalipov S (2014) Concise review: parthenote stem cells for regenerative medicine: genetic, epigenetic, and developmental features. Stem Cells Transl Med 3(3):290–298. https://doi.org/10.5966/sctm.2013-0127
De Sousa PA, Tye BJ, Bruce K, Dand P, Russell G, Collins DM, Greenshields A et al (2016) Derivation of the clinical grade human embryonic stem cell line RCe013-A (RC-9). Stem Cell Res 17(1):36–41. https://doi.org/10.1016/j.scr.2016.04.020
de Wolf C, van de Bovenkamp M, Hoefnagel M (2017) Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. Cytotherapy 19(7):784–797. https://doi.org/10.1016/j.jcyt.2017.03.076
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, Deans RJ, Keating A, Prockop DJ, Horwitz EM (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy Position Statement. Cytotherapy 8(4):315–317. https://doi.org/10.1080/14653240600855905
FACT-JACIE International Standards for Hematopoietic Cellular Therapy: Collection, Processing, and Administration, seventh edition 7.0 (2018) Foundation for the accreditation of cellular therapy, Joint Accreditation Committee ISCT, EBMT
Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE (1999) The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 23(1):9–13. https://doi.org/10.1038/sj.bmt.1701530
Garitaonandia I, Gonzalez R, Christiansen-Weber T, Abramihina T, Poustovoitov M, Noskov A, Sherman G, Semechkin A, Snyder E, Kern R (2016) Neural stem cell tumorigenicity and biodistribution assessment for phase I clinical trial in Parkinson’s disease. Sci Rep 6(1):34478. https://doi.org/10.1038/srep34478
Gelati M, Profico D, Projetti-Pensi M, Muzi G, Sgaravizzi G, Vescovi AL (2013) Culturing and expansion of “clinical grade” precursors cells from the fetal human central nervous system. In: Reynolds BA, Deleyrolle LP (eds) Neural progenitor cells: methods and protocols. Methods in molecular biology. Humana Press, Totowa, NJ, pp 65–77. https://doi.org/10.1007/978-1-62703-574-3_6
Gharibi B, Hughes FJ (2012) Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells. Stem Cells Transl Med 1(11):771–782. https://doi.org/10.5966/sctm.2010-0031
Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T, Polak M, Kelly C, Feldman EL (2012) Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 30(6):1144–1151. https://doi.org/10.1002/stem.1079
Gonzalez R, Garitaonandia I, Poustovoitov M, Abramihina T, McEntire C, Culp B, Attwood J et al (2016) Neural stem cells derived from human parthenogenetic stem cells engraft and promote recovery in a nonhuman primate model of Parkinson’s disease. Cell Transplant 25(11):1945–1966. https://doi.org/10.3727/096368916X691682
Guadix JA, López-Beas J, Clares B, Soriano-Ruiz JL, Zugaza JL, Gálvez-Martín P (2019) Principal criteria for evaluating the quality, safety and efficacy of hMSC-based products in clinical practice: current approaches and challenges. Pharmaceutics 11(11). https://doi.org/10.3390/pharmaceutics11110552
Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs). b.r., 39.
Guidance for Human Somatic Cell Therapy and Gene Therapy (1998) U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. https://www.fda.gov/media/72402/download
Guidance for Industry Potency Tests for Cellular and Gene Therapy Products (2011) U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Final-Guidance-for-Industry%2D%2DPotency-Tests-for-Cellular-and-Gene-Therapy-Products.pdf
Guo X, Johe K, Molnar P, Davis H, Hickman J (2010) Characterization of a human fetal spinal cord stem cell line NSI-566RSC and its induction to functional motoneurons. J Tissue Eng Regen Med 4(3):181–193. https://doi.org/10.1002/term.223
Irion S, Zabierowski SE, Tomishima MJ (2017) Bringing neural cell therapies to the clinic: past and future strategies. Mol Ther Methods Clin Dev 4:72–82. https://doi.org/10.1016/j.omtm.2016.11.005
Isaev DA, Garitaonandia I, Abramihina TV, Zogovic-Kapsalis T, West RA, Semechkin AY, Müller AM, Semechkin RA (2011) In vitro differentiation of human parthenogenetic stem cells into neural lineages. Regen Med 7(1):37–45. https://doi.org/10.2217/rme.11.110
Khaddour K, Hana CK, Mewawalla P (2021) Hematopoietic stem cell transplantation. In: StatPearls. StatPearls Publishing, Treasure Island (FL). http://www.ncbi.nlm.nih.gov/books/NBK536951/
Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH (1994) Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84(5):1415–1420. https://doi.org/10.1182/blood.V84.5.1415.1415
Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M et al (2007) High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110(13):4576–4583. https://doi.org/10.1182/blood-2007-06-097386
Lehman N, Cutrone R, Raber A, Perry R, van’t Hof W, Deans R, Ting AE, Woda J (2012) Development of a surrogate angiogenic potency assay for clinical-grade stem cell production. Cytotherapy 14(8):994–1004. https://doi.org/10.3109/14653249.2012.688945
Lu M, Lu P, Xu M, Wang X, Cui A, Li Y, Wang X et al (2019) Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts. EBioMedicine 42:443–457. https://doi.org/10.1016/j.ebiom.2019.03.011
Lv F-J, Tuan RS, Cheung KMC, Leung VYL (2014) Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells 32(6):1408–1419. https://doi.org/10.1002/stem.1681
Main H, Hedenskog M, Acharya G, Hovatta O, Lanner F (2020) Karolinska Institutet human embryonic stem cell bank. Stem Cell Res 45:101810. https://doi.org/10.1016/j.scr.2020.101810
Mayani H (2019) Human hematopoietic stem cells: concepts and perspectives on the biology and use of fresh versus in vitro–generated cells for therapeutic applications. Curr Stem Cell Rep 5(3):115–124. https://doi.org/10.1007/s40778-019-00162-1
Mazzini L, Gelati M, Profico DC, Sgaravizzi G, Pensi MP, Muzi G, Ricciolini C et al (2015) Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med 13. https://doi.org/10.1186/s12967-014-0371-2
Migliaccio AR, Adamson JW, Stevens CE, Ludy Dobrila N, Carrier CM, Rubinstein P (2000) Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 96(8):2717–2722. https://doi.org/10.1182/blood.V96.8.2717
Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL (1997) Identification of a lineage of multipotent hematopoietic progenitors. Development (Cambridge, England) 124(10):1929–1939
Orozco-Fuentes S, Neganova I, Wadkin LE, Baggaley AW, Barrio RA, Lako M, Shukurov A, Parker NG (2019) Quantification of the morphological characteristics of HESC colonies. Sci Rep 9(1):1–11. https://doi.org/10.1038/s41598-019-53719-9
Pollock K, Stroemer P, Patel S, Stevanato L, Hope A, Miljan E, Dong Z, Hodges H, Price J, Sinden JD (2006) A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp Neurol Stem/Progenitor Cell Biol Stroke/Hypoxic-Ischemic Cerebral Injury 199(1):143–155. https://doi.org/10.1016/j.expneurol.2005.12.011
Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use; Guidance for Industry and Food and Drug Administration Staff. b.r., 28
Rehakova D, Souralova T, Koutna I (2020) Clinical-grade human pluripotent stem cells for cell therapy: characterization strategy. Int J Mol Sci 21(7):2435. https://doi.org/10.3390/ijms21072435
Robb KP, Fitzgerald JC, Barry F, Viswanathan S (2019) Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. Cytotherapy 21(3):289–306. https://doi.org/10.1016/j.jcyt.2018.10.014
Rodin S, Antonsson L, Hovatta O, Tryggvason K (2014) Monolayer culturing and cloning of human pluripotent stem cells on laminin-521–based matrices under Xeno-free and chemically defined conditions. Nat Protoc 9(10):2354–2368. https://doi.org/10.1038/nprot.2014.159
Rosati J, Ferrari D, Altieri F, Tardivo S, Ricciolini C, Fusilli C, Zalfa C et al (2018) Establishment of stable IPS-derived human neural stem cell lines suitable for cell therapies. Cell Death Dis 9(10):1–16. https://doi.org/10.1038/s41419-018-0990-2
Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM (2017) Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 6(12):2173–2185. https://doi.org/10.1002/sctm.17-0129
Scaradavou A, Smith KM, Hawke R, Schaible A, Abboud M, Kernan NA, Young JW, Barker JN (2010) Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transplant 16(4):500–508. https://doi.org/10.1016/j.bbmt.2009.11.013
Shafa M, Yang F, Fellner T, Rao MS, Baghbaderani BA (2018) Human-induced pluripotent stem cells manufactured using a current good manufacturing practice-compliant process differentiate into clinically relevant cells from three germ layers. Front Med 5. https://doi.org/10.3389/fmed.2018.00069
Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C, Millar B et al (2000) A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 26(5):489–496. https://doi.org/10.1038/sj.bmt.1702542
Sullivan S, Stacey GN, Akazawa C, Aoyama N, Baptista R, Bedford P, Griscelli AB et al (2018) Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med 13(7):859–866. https://doi.org/10.2217/rme-2018-0095
Sullivan S, Fairchild PJ, Marsh SGE, Müller CR, Turner ML, Song J, Turner D (2020) Haplobanking induced pluripotent stem cells for clinical use. Stem Cell Res 49:102035. https://doi.org/10.1016/j.scr.2020.102035
Sun Y, Pollard S, Conti L, Toselli M, Biella G, Parkin G, Willatt L, Falk A, Cattaneo E, Smith A (2008) Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture. Mol Cell Neurosci 38(2):245–258. https://doi.org/10.1016/j.mcn.2008.02.014
Tang Y, Yu P, Lin C (2017) Current progress in the derivation and therapeutic application of neural stem cells. Cell Death Dis 8(10):e3108–e3108. https://doi.org/10.1038/cddis.2017.504
Tannenbaum SE, Turetsky TT, Singer O, Aizenman E, Kirshberg S, Ilouz N, Gil Y et al (2012) Derivation of xeno-free and GMP-grade human embryonic stem cells – platforms for future clinical applications. PLoS One 7(6):e35325. https://doi.org/10.1371/journal.pone.0035325
Tao H, Han Z, Han ZC, Li Z (2016) Proangiogenic features of mesenchymal stem cells and their therapeutic applications. Review article. Stem Cells Int Hindawi 6. https://doi.org/10.1155/2016/1314709
Thej C, Ramadasse B, Walvekar A, Majumdar AS, Balasubramanian S (2017) Development of a surrogate potency assay to determine the angiogenic activity of Stempeucel®, a pooled, ex-vivo expanded, allogeneic human bone marrow mesenchymal stromal cell product. Stem Cell Res Ther 8(1):47. https://doi.org/10.1186/s13287-017-0488-3
Thomas RJ, Hope AD, Hourd P, Baradez M, Miljan EA, Sinden JD, Williams DJ (2009) Automated, serum-free production of CTX0E03: a therapeutic clinical grade human neural stem cell line. Biotechnol Lett 31(8):1167–1172. https://doi.org/10.1007/s10529-009-9989-1
Tirughana R, Metz MZ, Li Z, Hall C, Hsu D, Beltzer J, Annala AJ, Oganesyan D, Gutova M, Aboody KS (2018) GMP production and scale-up of adherent neural stem cells with a quantum cell expansion system. Mol Ther Methods Clin Dev 10:48–56. https://doi.org/10.1016/j.omtm.2018.05.006
Torre ML, Lucarelli E, Guidi S, Ferrari M, Alessandri G, De Girolamo L, Pessina A, Ferrero I (2014) Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application. Stem Cells Dev 24(6):677–685. https://doi.org/10.1089/scd.2014.0299
Vanneaux V (2019) Induced pluripotent stem cells for clinical use. Update on mesenchymal and induced pluripotent stem cells. IntechOpen. https://doi.org/10.5772/intechopen.88878
Vitillo L, Durance C, Hewitt Z, Moore H, Smith A, Vallier L (2020) GMP-grade neural progenitor derivation and differentiation from clinical-grade human embryonic stem cells. Stem Cell Res Ther 11(1):406. https://doi.org/10.1186/s13287-020-01915-0
Wagner JE, Barker JN, DeFor TE, Scott Baker K, Blazar BR, Eide C, Goldman A et al (2002) Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 100(5):1611–1618. https://doi.org/10.1182/blood-2002-01-0294
Wagner W, Ho AD, Zenke M (2010) Different facets of aging in human mesenchymal stem cells. Tissue Eng B Rev 16(4):445–453. https://doi.org/10.1089/ten.teb.2009.0825
Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, John C. Rothwell, et al. (1997) Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease. Ann Neurol 42(1):95–107. https://doi.org/10.1002/ana.410420115
Wognum B, Yuan N, Lai B, Miller CL (2013) Colony forming cell assays for human hematopoietic progenitor cells. In: Helgason CD, Miller CL (eds) Basic cell culture protocols. Methods in molecular biology, vol 946. Humana Press, Totowa, NJ, pp 267–283. https://doi.org/10.1007/978-1-62703-128-8_17
Xiang M, Lu M, Quan J, Xu M, Meng D, Cui A, Li N et al (2019) Direct in vivo application of induced pluripotent stem cells is feasible and can be safe. Theranostics 9(1):290–310. https://doi.org/10.7150/thno.28671
Xu L, Yan J, Chen D, Welsh AM, Hazel T, Johe K, Hatfield G, Koliatsos VE (2006) Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 82(7):865–875. https://doi.org/10.1097/01.tp.0000235532.00920.7a
Ye J, Bates N, Soteriou D, Grady L, Edmond C, Ross A, Kerby A et al (2017) High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos. Stem Cell Res Ther 8(1). https://doi.org/10.1186/s13287-017-0561-y
Zhang H, Bingnan S, Jiao L, Xu Z-H, Zhang C-J, Nie J, Gao M-L, Zhang YV, Jin Z-B (2021) Transplantation of GMP-grade human iPSC-derived retinal pigment epithelial cells in rodent model: the first pre-clinical study for safety and efficacy in China. Ann Transl Med 9(3). https://doi.org/10.21037/atm-20-4707
Acknowledgments
This work was supported by the European Regional Development Funds—Projects ENOCH (No. CZ.02.1.01/0.0/0.0/16_019/0000868) and MAGNET (No. CZ.02.1.01/0.0/0.0/15_003/0000492). Supported by Ministry of Health of the Czech Republic, grant nr. NV18-08-00412. All rights reserved. Supported by the European Regional Development Fund—Project CZECRIN_4 PACIENTY (No. CZ.02.1.01/0.0/0.0/16_013/0001826). Tereza Souralova is a Brno Ph.D. Talent Scholarship holder and is funded by the Brno City Municipality.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Souralova, T., Rehakova, D., Tesarova, L., Hampl, A., Koutna, I. (2022). Characterization of Clinical-Grade Stem Cells: Microscopic, Cellular, Molecular, and Functional Characterization of Stem Cells and Their Products According to Regulatory Requirements for FDA Approval. In: Khan, F.A. (eds) Stem Cell Production. Springer, Singapore. https://doi.org/10.1007/978-981-16-7589-8_8
Download citation
DOI: https://doi.org/10.1007/978-981-16-7589-8_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-7588-1
Online ISBN: 978-981-16-7589-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)